Replies to post #83102 on Biotech Values

[turtlepower]

p II stat sig - mcbio I absolutely agree with you. Drugs with strong results in PII appear to perform a lot better during PIII though I believe a recent example to the contrary was AEZSs cetrorelix which I believe did very well in its PII trials. I think though that with sufficient hedging if the reward is well worth the risk it is quite reasonable to invest in stocks like ACAD. In some cases if one does adequate research to figure out what the result of a negative outcome could be then one could even make money from that though it would still be a substantial risk and the amount of money made from a negative outcome is far less than that of a positive outcome.